Rossari Biotech Limited stock analysis

Expanded Manufacturing Platform Capacity additions at Dahej and ethoxylation expansion strengthened Rossari’s integrated manufacturing base and improved readiness for future demand. Shareholder and Governance Focus Leadership additions, disciplined debt reduction plans and dividend recommendation reflected Rossari’s focus on governance, returns and long-term value creation. Innovation Infrastructure Rossari Global Re

We remain focused on deepening our presence in existing geographie s while selectively expanding into markets that offer attractive long-term potential. During the quarter, we further strengthened our presence in Southeast Asia through a greenfield blending plant in Thailand. This facility will enhance our ability to offer customized formulations, respond faster to local market requirements, and improve supply chain

Utilization levels across our manufacturing capacities improved during the quarter, contributing to the growth in revenue and EBITDA. Our focus now is on driving these assets towards optimal utilization, improving the product mix, and generating stronger operating leverage from the investments made over the past few years. Our balance sheet remains healthy, supporting strong liquidity and a comfortable leverage.

The Global Growth Engine Revenue Contribution 26:74 ROW : India 8 Manufacturing Footprints 80+ Countries 2,800+ Customers 07Rossari Biotech Limited Corporate Overview Statutory Reports Financial Statements Rossari's sustained trajectory of outperforming industry growth is underpinned by a carefully cultivated competitive moat. In 2025-26, the Company recorded significant market share gains, culminating in a strong fu

This percentage has remained the same while the absolute number has gone up. Compared to the Q1 of last year, the export growth is almost 20 %- 21%. Our target is to keep growing the export business, while the domestic business is also growing, so generally the percentage remains around between 23 %-24%- 25%.

These certifications enable our global clientele to meet stringent requirements while achieving superior fabric performance. The AHN Division, offering over 90 specialised products across poultry feed, aquaculture, and pet grooming, maintained strong operational momentum. This was supported by a strategic pivot to high-margin therapeutic additives, digestive enzymes, and advanced gut health formulations.

The scale achieved across our core businesses, improving utilization of our expanded capacities, a growing pipeline of new products and applications, and continued progress across international markets provide a strong foundation for the next phase of growth. Our priorities remain centred on disciplined execution, margin improvement, and generating stronger returns for the business platform we have built. Thank you o

In 2025-26 alone, the integrated team developed and launched over 70 new products, across personal care, agrochemicals, and technical textiles. By bringing synthesis, biotechnology, and application labs under one roof, the Company has significantly reduced the time from idea generation to full-scale commercial production. The Shift to Continuous Flow Chemistry: Beyond product formulation, the Company’s R&D is fundame